New ways to develop new ways to activate T-cell anti-cancer response received $80 million in assistance

Recently, ATP Company announced the establishment of Marengo Therapeutics to develop new antibodies targeting T cell receptor (TCR) Vβ variants to achieve the effect of selectively activating anti-tumor T cells, and plans to promote the company’s lead drug candidates in 2022 To the clinic

Although in the field of immuno-oncology, therapies based on activated T cells have made significant progress, less than one-third of patients receiving current treatment methods have a durable response

The company's research and development team found that bacterial superantigens in nature can activate specific T cells by binding to the TCRVβ chain

The company's lead drug candidate STAR0602 is an antibody fusion molecule

Note: The original text has been deleted

Reference materials:

[1] Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform.